Louveciennes, France - January 24th, 2012 - Aptar Pharma, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, today announces the opening of a new facility near Mumbai, India.


Growing expansion in India
Established in 1999 in Mumbai, Aptar Pharma is the market leader in India.
Aptar Pharma provides innovative and proven aerosol, spray and dispensing systems to biotechnology, healthcare and pharmaceutical companies in India.
Located at Rabale, Navi Mumbai, this new facility is the first of its kind. It will be key to furthering Aptar Pharma's commitment to provide world class quality products coupled with the outstanding responsiveness requested by our Indian customers.
The facility will fully support our customers' growth in the pharma market.
This new state-of-the-art manufacturing site was officially inaugurated on January 21st, 2012 in the presence of:

  • the ACG Worldwide Chairman, Mr. Ajit Singh


  • the President of the Indian Pharmaceutical Association (IPA), Dr C. Gopalakrishna Murty
  • Business partners and suppliers as well as AptarGroup senior management representatives including our CEO Mr. Stephen J. Hagge and AptarGroup board member Mr. P. Pfeiffer.

This site includes an ISO 7 cleanroom where main production will focus on the DF30 metering valve platform for pMDIs and on spray pump assembly.


Leveraging local employment opportunities
Currently Aptar Pharma India has some 30 employees. With the opening of the new Mumbai manufacturing site, this team will be reinforced with a number of different employment profiles.
Recognized as the market leader in Asia, including India, Aptar Pharma will become a key local employer and will continue to expand its activity, leveraging an in-depth network of local partners to forge strong links with a wide range of local players, including those in research, industry, academia and regulatory bodies.
"With the launch of the second Aptar Pharma manufacturing site in Asia, after Suzhou in China, we are on track to meet our main objective of better serving Indian customers by providing locally manufactured devices", said Marc Prieur, President Aptar Pharma Asia. "This state-of-the-art manufacturing site, along with a highly skilled local team, shows Aptar Pharma's strong commitment to the Indian Pharmaceutical industry".
About Aptar Pharma

Aptar Pharma is part of the Aptargroup family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage. We create innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world. We provide our customers with a wide range of delivery technologies and analytical services backed by years of proven expertise. For more information, visit www.aptar.com/pharma
Aptargroup (NYSE: ATR) is headquartered in the US and has manufacturing sites in North America, Europe, Asia and South America. For more information, visit www.aptar.com.


Press Contacts

Elisa Eschylle, Events and Press relations manager
Tel.: + 33 (0)1 39 17 20 41
 Email : [email protected]
Marion Baschet Vernet, Press attaché
 Tel.: +44 (0)797 609 4100
 Email : [email protected]


Suggested Articles

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

Pfizer, GSK, BIO and others are all planning vaccine messages for fall.